Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
about
Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.Transdermal patches: history, development and pharmacology.Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection.Rivastigmine in Parkinson's disease dementia.Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer's Disease.Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity.Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.Transdermal patches for the treatment of neurologic conditions in elderly patients: a review.Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.Therapeutic dosage assessment based on population pharmacokinetics of a novel single-dose transdermal donepezil patch in healthy volunteers.Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.A metoprolol-terbinafine combination induced bradycardia.Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants.A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting.Drug delivery in the twenty-first century: a new paradigm.Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch.Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats.Drug Delivery and Transport into the Central Circulation: An Example of Zero-Order In vivo Absorption of Rotigotine from a Transdermal Patch Formulation.Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.Therapeutics of Neurotransmitters in Alzheimer's Disease.An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine.Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
P2860
Q33937187-E703E237-CA64-4DDF-94DF-D70FFA0D48DAQ34327769-1EDCC324-21B6-4699-9C23-54770570B51EQ35195218-958BFBBA-268B-4361-B4F1-B36FDB38E3EAQ35484265-880DBD44-8104-43FD-9793-03FE7A7A7909Q36648773-FD7D2A73-8956-47F9-8697-A4D5C1035F08Q37232006-EED462C7-AE27-4C25-A0B3-DD976D67DC05Q37325828-BFEA3540-1BCA-498B-9260-75476D678CB1Q37358548-C20D8017-10F1-486D-99D8-4CF710692C57Q37385577-2045B811-A575-4CA1-8A15-3CA07C0DBA78Q37597753-352EC99D-DB55-44D7-B403-3C62D35065AEQ37658872-D3A130C6-818D-4775-BF84-1A278B1E5F3FQ37881946-1F18AFA5-66D3-480B-BB44-64708391495EQ37895257-02A78235-3621-4E60-B6D8-18CECF6D652DQ37952853-20FD924B-993D-4B2B-A06F-DE0CE73BD50CQ37997774-D986DDD9-4550-4043-B92A-F43CF997D95EQ38225721-F76DE24C-DFD1-44C3-B4A7-C599AA4F10AEQ38247181-1855F9CE-DF26-4DFF-ABF2-1736AB3DF396Q38350602-8E333399-97A6-433E-8B74-3FF3B8A73EACQ38801735-3A7830E0-8CC4-4AC1-86C5-5ABA0E30250CQ38906350-2BFF8EC3-FDE4-4B70-8817-6217708C13B6Q38990600-3EAAA228-1B1E-429E-A854-3E624817F914Q39415447-57543DE8-CBE9-40DF-BD11-B683421FDE0CQ40899039-2BDFCD2F-68AB-46CC-B1E5-4875B31D0BB8Q41929679-177C7928-246D-4D4B-9E65-AE3E0B8813ACQ42705397-A9918877-68AF-4632-9540-6E5520F7656BQ43609548-1F54DC76-D2B7-42FB-B881-B83D90DD0BAFQ43613870-378F55A9-C4D8-415B-A575-2E39AA0A91EDQ45756592-272DA010-428D-4F9E-A0F6-452DB3D7A6E0Q46043544-22ACCC54-EFDF-4963-86CB-690AEFD1BC2FQ46107336-472FF0EA-F4D5-44D1-A1BA-94E2FD11AC88Q46373585-C30553CD-DE1A-42F1-92E3-41DBE94A0686Q47563667-69CE4FE7-20DB-495A-867D-15EC7E389050Q47801349-62B9EAF9-92FE-4A56-9135-BA82D980E5FDQ47878674-6CE307C4-E22D-4FC2-8465-CDA153668E4BQ48439989-52A1806A-3594-48D9-9220-DFE09EA56531Q49672905-A2D9BB2B-3498-4824-ACEF-667757F2D0BBQ50328399-58AB6D7B-2995-4A6F-B8B5-4456FA658E2EQ50715713-ADDCDFDB-B559-4650-AC08-3F236A7BF26DQ50780492-2D1BAA1C-03A1-4318-8063-D71BEC9CE116Q51491144-C5FD3FF6-45EA-4A68-B77F-E52D5640CB0F
P2860
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@en
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@nl
type
label
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@en
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@en
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@nl
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacod ...... Alzheimer's disease patients.
@en
P2093
H Schmidli
H-La Huang
L Ereshefsky
M T Leibowitz
S Appel-Dingemanse
P2860
P304
P356
10.1038/SJ.CLPT.6100242
P407
P577
2007-05-23T00:00:00Z